Modern approaches to the choice of antimicrobial agents for pelvic inflammatory diseases: the role of innovative microbiological methods




sexually transmitted diseases, pelvic inflammatory diseases, opportunistic flora, antibiotic resistance, antibiotic therapy control strategy


Pelvic inflammatory diseases (PID) is comprehensive term that includes infectious-inflammatory lesions of the endometrium, fallopian tubes and ovaries. PID is one of the main causes of treatment of reproductive aged women by gynecologists, and the cause of impaired reproductive function, chronic pelvic pain syndrome and ectopic pregnancy in the absence of treatment.

This article provides an overview of current clinical guidelines for diagnosis and general treatment approaches of PID. A detailed analysis of modern scientific researches dedicated to the change of the PID’s pathogens structure and the peculiarities of their clinical presentation today. This analysis showed that despite the leading role of sexually transmitted infections, opportunistic flora is of great importance in the pathogenesis of this pathology. Features of the PID’s clinical course include an increase in the recurrence frequency. These features are associated with the growing worldwide phenomenon of antibiotic resistance.

Data from the European Antimicrobial Resistance Surveillance Network report at the European Center for Disease Control “Antibiotic Resistance Surveillance 2017” on the resistance prevalence of clinically relevant pathogenic bacteria to the most commonly used antimicrobials. Nonspecific bacterial pathogens of PID in the European region show a fairly high rate of antibiotic resistance. At the same time, the experience of many countries demonstrates the effectiveness of the strategy of antimicrobial stewardship strategy, one of the main principles of which is microbiological research whenever possible when prescribing antibacterial therapy. Thus regardless of whether representative of the opportunistic flora is a direct cause of a severe PID course or secondary due to previous sexually transmitted diseases, its identification and antibiotic susceptibility testing is critical for the effective treatment of PID (especially severe forms) given the prevalence of antibiotic resistance.

Author Biographies

О. А. Бурка, O.O. Bogomolets National Medical University Medical Laboratory “DILA”, Kyiv

PhD, associate professor of the Obstetrics and Gynecology Department No. 1

Scientific consultant

Т. М. Тутченко, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”, SSI “Centre of Innovative Medical Technologies of the NAS of Ukraine Medical Laboratory “DILA”, Kyiv

PhD, senior researcher

Scientific consultant

Н. Ю. Педаченко, P.L. Shupik National Medical Academy of the Postgraduate Education, Kyiv

MD, professor at the Department of Obstetrics, Gynecology and Perinatology

О. М. Кудлай, Military unit, Kyiv

PhD, obstetrician-gynecologist, head of the gynecological department


  1. Brunham, R.C., Gottlieb, S.L., Paavonen, J. «Pelvic Inflammatory Disease.» N Engl J Med 372 (2015): 2039–48. DOI: 10.1056/NEJMra1411426
  2. Ross, J., Guaschino, S., Cusini, M., Jensen, J. «2017 European guideline for the management of pelvic inflammatory disease.» Int J STD AIDS 29 (2018): 108–14. DOI: 10.1177/0956462417744099
  3. Greydanus, D.E., Bacopoulou, F. «Acute pelvic inflammatory disease.» Pediatr Med 2 (2019): 36. DOI: 10.21037/pm.2019.07.05
  4. Curry, A., Williams, T., Penny, M.L. «Pelvic Inflammatory Disease: Diagnosis, Management, and Prevention.» Am Fam Physician 100 (2019): 357–64.
  5. Das, B.B., Ronda, J., Trent, M. «Pelvic inflammatory disease: Improving awareness, prevention, and treatment.» Infect Drug Resist 9 (2016): 191–7. DOI: 10.2147/IDR.S91260
  6. Moreno, I., Franasiak, J.M. «Endometrial microbiota – new player in town.» Fertil Steril 108 (2017): 32–9. DOI: 10.1016/J.FERTNSTERT.2017.05.034
  7. Khan, K.N., Fujishita, A., Hiraki, K., et al. «Bacterial contamination hypothesis: a new concept in endometriosis.» Reprod Med Biol 17 (2018): 125–33. DOI: 10.1002/rmb2.12083
  8. Tai, F.-W., Chang, C., Chiang, J.-H., et al. «Association of Pelvic Inflammatory Disease with Risk of Endometriosis: A Nationwide Cohort Study Involving 141,460 Individuals.» J Clin Med 7 (2018): 379. DOI: 10.3390/jcm7110379
  9. Stewart, L.M., Stewart, C.J.R., Spilsbury, K., et al. «Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.» Gynecol Oncol (2020). DOI:10.1016/j. ygyno.2020.01.027
  10. Zhou, Z., Zeng, F., Yuan, J., et al. «Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis.» Cancer Causes Control 28 (2017): 415–28. DOI: 10.1007/s10552-017-0873-3
  11. Frain, A., Fielder, J. «Pelvic inflammatory disease: a review.» O&G Magazine 21.4 (2019). Available from: [], last accessed Feb 22, 2020.
  12. Haque, M. «Antibiotic use, antibiotic resistance, and anti stewardship – a global public consequences.» Bangladesh J Med Sci 18 (2019): 169–70. DOI: 10.3329/bjms.v18i2.40680
  13. Chernick, L.S. «Tubo-Ovarian Abscesses in Nonsexually Active Adolescents: A Rare but Consequential Miss.» J Adolesc Heal 65 (2019): 175–6. DOI: 10.1016/j.jadohealth.2019.04.006
  14. Getahun, A.S., Limaono, J., Ligaitukana, R., et al. «Ovarian abscess caused by Salmonella enterica serovar Typhi: A case report.» J Med Case Rep 13 (2019). DOI: 10.1186/s13256-019-2229-y
  15. Tyan, P., Abi-Khalil, E., Dwarki, K., Moawad, G. «First Described Case of Group B Streptococcus Pelvic Abscess in a Patient with No Medical Comorbidities.» Case Rep Obstet Gynecol 2016 (2016): 1–4. DOI: 10.1155/2016/3724706
  16. Lusby, H., Brooks, A., Hamayoun, E., Finley, A. «Uncommon cause of pelvic inflammatory disease leading to toxic shock syndrome.» BMJ Case Rep 2018 (2018). DOI: 10.1136/bcr-2018-224955
  17. Felz, M.W., Apostol, C.J. «Fatal pneumococcal sepsis from a tuboovarian abscess.» J Am Board Fam Pract 17 (2004): 68–70. DOI: 10.3122/jabfm.17.1.68
  18. Algren, S.D., Strickland, J.L. «Beta hemolytic Streptococcus group F causing pelvic inflammatory disease in a 14-year-old girl.» J Pediatr Adolesc Gynecol 18 (2005): 117–9. DOI: 10.1016/j.jpag.2005.01.007
  19. Yamamoto, T., Kenzaka, T., Mizuki, S., et al. «An extremely rare case of tubo-ovarian abscesses involving corynebacterium striatum as causative agent.» BMC Infect Dis 16 (2016): 1–6. DOI: 10.1186/s12879-016-1860-0
  20. Taylor, G.M., Erlich, A.H., Wallace, L.C., et al. «A tubo-ovarian abscess mimicking an appendiceal abscess: a rare presentation of Streptococcus agalactiae.» Oxford Med Case Reports 2019 (2019). DOI: 10.1093/omcr/omz071
  21. To, V., Gurberg, J., Krishnamurthy, S. «Tubo-Ovarian Abscess Caused by Candida Albicans in an Obese Patient.» J Obstet Gynaecol Canada 37 (2015): 426–9. DOI: 10.1016/S1701-2163(15)30257-7
  22. Okmen, F., Ekici, H., Ari, S.A. «Case Report of a Tubo-ovarian Abscess Caused by Candida kefyr.» J Obstet Gynaecol Canada 40 (2018): 1466–7. DOI: 10.1016/j. jogc.2018.04.025
  23. Trent, M., Bass, D., Ness, R.B., Haggerty, C. «Recurrent PID, subsequent STI, and reproductive health outcomes: Findings from the PID evaluation and clinical health (PEACH) study.» Sex Transm Dis 38 (2011): 879–81. DOI: 10.1097/OLQ.0b013e31821f918c
  24. Safrai, M., Rottenstreich, A., Shushan, A., et al. «Risk factors for recurrent Pelvic Inflammatory Disease.» Eur J Obstet Gynecol Reprod Biol 244 (2020): 40–4. DOI: 10.1016/j. ejogrb.2019.11.004
  25. Sharma, H., Tal, R., Clark, N.A., Segars, J.H. «Microbiota and pelvic inflammatory disease.» Semin Reprod Med 32 (2014): 43–9. DOI: 10.1055/s-0033-1361822
  26. Taylor, B.D., Darville, T., Haggerty, C.L. «Does bacterial vaginosis cause pelvic inflammatory disease?» Sex Transm Dis 40 (2013): 117–22. DOI: 10.1097/OLQ.0b013e31827c5a5b
  27. Centers for Disease Control and Prevention. Pelvic Inflammatory Disease (PID) – 2015 STD Treatment Guidelines. Available from: [], last accessed Feb 11, 2020.
  28. Haggerty, C.L. Totten, P.A., Tang, G., et al. «Identification of novel microbes associated with pelvic inflammatory disease and infertility.» Sex Transm Infect 92 (2016): 441–6. DOI: 10.1136/sextrans-2015-052285
  29. Price, M.J., Ades, A.E., Welton, N.J., et al. «Pelvic inflammatory disease and salpingitis: Incidence of primary and repeat episodes in England.» Epidemiol Infect 145 (2017): 208–15. DOI: 10.1017/S0950268816002065
  30. Workowski, K.A., Bolan, G.A. «Centers for Disease Control and Prevention, Sexually transmitted diseases treatment guidelines, 2015.» MMWR Recomm Reports Morb Mortal Wkly Report Recomm Reports 64 (2015): 1–137.
  31. Soper, D.E. Brockwell, N.J., Dalton, H.P., Johnson, D. «Observations concerning the microbial etiology of acute salpingitis.» Am J Obstet Gynecol 170 (1994): 1008–17. DOI: 10.1016/S0002-9378(94)70094-X
  32. Gradison, M. «Pelvic Inflammatory Disease.» Am Fam Physician 85.8 (2012): 791–6.
  33. Price, M.J., Ades, A.E., De Angelis, D., et al. «Risk of pelvic inflammatory disease following chlamydia trachomatis infection: Analysis of prospective studies with a multistate model.» Am J Epidemiol 178 (2013): 484–92. DOI: 10.1093/aje/kws583
  34. Hoenderboom, B.M., Van Benthem, B.H.B., Van Bergen, J.E.A.M., et al. «Relation between Chlamydia trachomatis infection and pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility in a Dutch cohort of women previously tested for chlamydia in a chlamydia screening trial.» Sex Transm Infect 95 (2019): 300–6. DOI: 10.1136/sextrans-2018-053778
  35. Burnett, A.M., Anderson, C.P., Zwank, M.D. «Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis.» Am J Emerg Med 30 (2012): 1114–7. DOI: 10.1016/J.AJEM.2011.07.014
  36. Jossens, R.M.O., Schachter, J., Sweet, R.L. «Risk Factors Associated With Pelvic Inflammatory Disease of Differing Microbial Etiologies.» Obstet Gynecol 83 (1994): 989–97. DOI: 10.1097/00006250-199406000-00019
  37. Ness, R.B., Soper, D.E., Holley, R.L., et al. «Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial.» Am J Obstet Gynecol 186 (2002): 929–37. DOI: 10.1067/mob.2002.121625
  38. Goller, J.L., De Livera, A.M., Fairley, C.K., et al. «Characteristics of pelvic inflammatory disease where no sexually transmitted infection is identified: A cross-sectional analysis of routinely collected sexual health clinic data.» Sex Transm Infect 93 (2017): 68–70. DOI: 10.1136/sextrans-2016-052553
  39. Ness, R., Kip, K., Hillier, S., et al. «A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease.» American Journal of Epidemiology 162.6 (2005): 585–90. DOI: 10.1093/aje/kwi243
  40. Miller, J.M., Binnicker, M.J., Campbell, S., et al. «A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiologya.» Clin Infect Dis 67 (2018): 813–6. DOI: 10.1093/cid/ciy584
  41. Chappell, C.A., Wiesenfeld, H.C. «Pathogenesis, diagnosis, and management of severe pelvic inflammatory disease and tuboovarian abscess.» Clin Obstet Gynecol 55 (2012): 893–903. DOI: 10.1097/GRF.0b013e3182714681
  42. MacGowan, A., Macnaughton, E. «Antibiotic resistance.» Med (United Kingdom) 45 (2017): 622–8. DOI: 10.1016/j.mpmed.2017.07.006
  43. Munita, J.M., Arias, C.A. «Mechanisms of Antibiotic Resistance.» In: Virulence Mechanisms of Bacterial Pathogens, 5th Edition. American Society for Microbiology (2016). DOI: 10.1128/9781555819286.CH17
  44. Baylay, A.J., Piddock, L.J.V., Webber, M.A. «Molecular Mechanisms of Antibiotic Resistance – Part I.» In: Bact. Resist. to Antibiot. – From Mol. to Man. John Wiley & Sons Ltd. (2020). DOI: 10.1002/9781119593522
  45. Savaris, R.F., Fuhrich, D.G., Duarte, R.V., et al. «Antibiotic therapy for pelvic inflammatory disease.» Cochrane Database Syst Rev 2017 (2017). DOI: 10.1002/14651858.CD010285.pub2
  46. European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2017. Available from: [], last accessed Feb 22, 2020.



How to Cite

Бурка, О. А., Тутченко, Т. М., Педаченко, Н. Ю., & Кудлай, О. М. (2020). Modern approaches to the choice of antimicrobial agents for pelvic inflammatory diseases: the role of innovative microbiological methods. REPRODUCTIVE ENDOCRINOLOGY, (51), 25–31.